Ocuphire Pharma Investor Presentation Deck
Corporate Highlights
Late-Stage Clinical Candidates for Retinal Diseases Represent Multi-Billion Dollar Opportunity
*
APX3330: Paradigm Changing, Non-invasive, Safe Oral Tablet for millions of NPDR patients that are currently left untreated
Ref-1, a novel, dual target (angiogenesis and inflammation) for retinal diseases
ZETA-1 Phase 2 demonstrated slowing progression of Diabetic Retinopathy (DR) with statistically significant efficacy on
potential Phase 3 registration endpoint
●
●
Nyxol: Eyedrops for refractive disorders
Global License Agreement with Viatris to Fund all Development and Commercialization for Nyxol Indications:
Reversal of Mydriasis (RM)- PDUFA Date on September 28, 2023. Approval would trigger $10M milestone
Presbyopia- currently in Phase 3
Dim Light Disturbances- currently in Phase 3
Ocuphire
●
Strong Financial Position to Advance APX3330
PHARMA
●
3View entire presentation